Brief: Ascentage Pharma Group International Says NMPA Recommended Olverembatinib (Hqp1351) For Breakthrough Therapy Designation
31/05/2023 01:00
May 31 (Reuters) - Ascentage Pharma Group International
6855.HK :
* CENTER FOR DRUG EVALUATION OF NMPA RECOMMENDED
OLVEREMBATINIB
(HQP1351) FOR BREAKTHROUGH THERAPY DESIGNATION
Further company coverage: 6855.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up